Article information
Abstract
Metabolic complications continue to play a major role in the management of HIV infection. Dyslipidemia associated with HIV infection and with the use of combined antiretroviral therapy includes elevations in triglycerides, reduced high-density cholesterol, and variable increases in low-density and total cholesterol. The association between dyslipidemia and specific antiretroviral agents has been underscored. Multiple pathogenic mechanisms by which HIV and antiretroviral agents lead to dyslipidemia have been hypothesized, but they are still controversial. The potential clinical and pathological consequences of HIV-associated hyperlipidemia are not completely known, but several studies reported an increased risk of coronary artery disease in HIV-positive individuals receiving combined antiretroviral therapy. HIV-infected persons who have hyperlipidemia should be managed similarly to those without HIV infection in accordance with the National Cholesterol Education Program. Life style changes are the primary target. Statins and fibrates and/or modification in antiretroviral therapy are possible approaches to this problem.
Keywords:
HIV/AIDS
dyslipidemia
combined antiretroviral therapy
nutrition, Public Health
Full text is only aviable in PDF
References
[1.]
F.J. Palella Jr, K.M. Delaney, A.C. Moorman, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med, 338 (1998), pp. 853-860
[2.]
S.H. Tuboi, M.W.G. Brinkhof, M. Egger, et al.
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.
J Acquir Immune Defic Syndr, 45 (2007), pp. 52-59
[3.]
J.R. Marins, L.F. Jamal, S.Y. Chen, et al.
Dramatic improvement in survival among adult Brazilian AIDS patients.
AIDS, 17 (2003), pp. 1675-1682
[4.]
P. Braitstein, M.W. Brinkhof, F. Dabis, et al.
Mortality of HIV- 1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Lancet, 367 (2006), pp. 817-824
[5.]
C.T. Fang, Y.Y. Chang, H.M. Hsu, et al.
Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.
Q J Med, 100 (2007), pp. 97-105
[6.]
N. Lohse, A.B. Hansen, J. Gerstoft, N. Obel.
Improved survival in HIV-infected persons: consequences and perspectives.
J Antimicrob Chemother, 60 (2007), pp. 461-463
[7.]
A. Carr, K. Sâmaras, S. Burton, et al.
A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors.
AIDS, 12 (1998), pp. 51-58
[8.]
V.S. Mattevi, A.S. Gasparotto, R.K. Lazzaretti, et al.
Apolipoprotein B gene polymorphisms are associated with higher cholesterol levels in HIV-infected individuals on HAART.
Antiviral Therapy, 14 (2009), pp. A52
[9.]
M.A. Noor.
The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications.
Curr HIV/AIDS Rep, 4 (2007), pp. 126-134
[10.]
A. Maagaard, D. Kvale.
Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?.
J Antimicrob Chemother, 64 (2009), pp. 901-909
[11.]
H.C. Côté.
Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction.
Curr Opin HIV AIDS, 2 (2007), pp. 253-260
[12.]
A. Carr, D.A. Cooper.
Adverse effects of antiretroviral therapy.
Lancet, 356 (2000), pp. 1423-1430
[13.]
N. Friis-Møller, C.A. Sabin, R. Weber, et al.
Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study.
AIDS, 17 (2003), pp. 1179-1193
[14.]
C.A. Sabin, S.W. Worm, D:A:D Study Group, et al.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
Lancet, 371 (2008), pp. 1417-1426
[15.]
S. Grinspoon, A. Carr.
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
N Engl J Med, 352 (2005), pp. 48-62
[16.]
A. Carr, K. Samaras, A. Thorisdottir, et al.
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.
Lancet, 353 (1999), pp. 2093-2099
[17.]
C. Gervasoni, A.L. Ridolfo, G. Trifiro, et al.
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
AIDS, 13 (1999), pp. 465-471
[18.]
S. Safrin, C. Grunfeld.
Fat Distribution and metabolic changes in patients with HIV infection.
AIDS, 13 (1999), pp. 2493-2505
[19.]
C. Grunfeld, P. Tien.
Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome.
Clin Infect Dis, 37 (2003), pp. 43-46
[20.]
B.F. Asztalos, E.J. Schaefer, K.V. Horvath, et al.
Protease inhibitor-based HAART, HDL CHD-risk in HIV-infected patients.
Atherosclerosis, 184 (2006), pp. 72-77
[21.]
J.H. Stein, M.A. Klein, J.L. Bellehumeur, et al.
Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
Circulation, 104 (2001), pp. 257-262
[22.]
C. Grunfeld, M. Pang, W. Doerrler, et al.
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
J Clin Endocrinol Metab, 74 (1992), pp. 1045-1052
[23.]
R. Zangerle, M. Sarcletti, H. Gallati, et al.
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.
J Acquir Immune Defic Syndr, 7 (1994), pp. 1149-1156
[24.]
M.P. Dubé, J.H. Stein, J.A. Aberg, et al.
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.
Clin Infect Dis, 37 (2003), pp. 613-627
[25.]
V. Mooser, A. Carr.
Antiretroviral therapy-associated hyperlipidaemia in HIV disease.
Curr Opin Lipidol, 12 (2001), pp. 313-319
[26.]
T.M. Riddle, D.G. Kuhel, L.A. Woollett, et al.
HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.
J Biol Chem, 276 (2001), pp. 37514-37519
[27.]
J.S. Liang, O. Distler, D.A. Cooper, et al.
HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.
Nat Med, 7 (2001), pp. 1327-1331
[28.]
C. Grunfeld, W. Doerrler, M. Pang, et al.
Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome.
J Clin Endocrinol Metab, 82 (1997), pp. 3734-3740
[29.]
M. Shahmanesh, H. Jaleel, Y. DeSilva, et al.
Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.
Sex Transm Infect, 77 (2001), pp. 283-286
[30.]
J. Hertel, H. Struthers, C.B. Horj, P.W. Hruz.
A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.
J Biol Chem, 279 (2004), pp. 55147-55152
[31.]
H. Murata, P.W. Hruz, M. Mueckler.
Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations.
AIDS, 16 (2002), pp. 859-863
[32.]
J.P. Bastard, M. Caron, H. Vidal, et al.
Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.
Lancet, 359 (2002), pp. 1026-1031
[33.]
D.C. Mynarcik, T. Combs, M.A. McNurlan, et al.
Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution.
J Acquir Immune Defic Syndr, 31 (2002), pp. 514-520
[34.]
P. Tontonoz, E. Hu, B.M. Spiegelman.
Regulation of adipocyte gene expression and differentiation bt peroxisome proliferator activated receptor c.
Curr Opin Genet Dev, 5 (1995), pp. 571-576
[35.]
K. Brinkman, J.A. Smeitink, J.A. Romijn, P. Reiss.
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy- related lipodystrophy.
Lancet, 354 (1999), pp. 1112-1115
[36.]
D. Nolan, E. Hammond, A. Martin, et al.
Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
AIDS, 17 (2003), pp. 1329-1338
[37.]
The DAD Study Group.
Class of antiretroviral drugs and the risk of myocardial infarction.
N Engl J Med, 356 (2007), pp. 1723-1735
[38.]
V.A. Triant, H. Lee, C. Hadigan, S.K. Grinspoon.
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.
J Clin Endocrinol Metab, 92 (2007), pp. 2506-2512
[39.]
S.A. Bozzette, C.F. Ake, H.K. Tam, et al.
Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
N Engl J Med, 348 (2003), pp. 702-710
[40.]
M.G. Law, N. Friis-Møller, W.M. El-Sadr, et al.
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the DAD Study.
HIV Medicine, 7 (2006), pp. 218-230
[41.]
W.M. El-Sadr, J.S. Lundgren, J.D. Neaton.
CD4+ count-guided interruption of antiretroviral treatment.
N Engl J Med, 355 (2006), pp. 2283-2296
[42.]
E. Martinez, M.A. García-Viejo, J.L. Blanco, et al.
Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.
Clin Infect Dis, 31 (2000), pp. 1266-1273
[43.]
L. Calza, R. Manfred, F. Chiodo.
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
J Antimicrob Chemother, 53 (2004), pp. 10-14
[44.]
M. Savês, F. Raffi, J. Capeau, et al.
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
Clin Infect Dis, 34 (2002), pp. 1396-1405
[45.]
A.C. Guimarães, M. Lima, E. Mota, et al.
The cholesterol level of a selected level of a selected Brazilian salaried population: biological and socioeconomic influences.
Cardiovascular Disease Prevention, 1 (1998), pp. 306-317
[46.]
J.L. Tang, J.M. Armitage, T. Lancaster, et al.
Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects.
BMJ, 316 (1998), pp. 1213-1220
[47.]
S. Yu-Poth, G. Zhao, T. Etherton, et al.
Effects of the National Cholesterol Education Programs Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis.
Am J Clin Nutr, 69 (1999), pp. 632-646
[48.]
S.P. Jones, D.A. Doran, P.B. Leatt, et al.
Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy.
AIDS, (2001), pp. 2049-2051
[49.]
L. Terry, E. Sprinz, R. Stein, et al.
Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
Med Sci Sports Exerc, 38 (2006), pp. 411-417
[50.]
K.V. Fitch, E.J. Anderson, J.L. Hubbard, et al.
Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome.
AIDS, 20 (2006), pp. 1843-1850
[51.]
C. Hadigan, S. Jeste, E.J. Anderson, et al.
Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution.
Clin Infect Dis, 33 (2001), pp. 710-717
[52.]
M.J. Batterham, D. Brown, C. Workman.
Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia.
AIDS, 17 (2002), pp. 1414-1416
[53.]
M.J. Batterham, R. Garsia, P.A. Greenop.
Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy Diet FRS Study.
AIDS, 14 (2000), pp. 1839-1843
[54.]
A. Barrios, F. Blanco, T. García-Benayas, et al.
Effect of dietary intervention on highly active antiretroviral therapy-treated dyslipidemia.
AIDS, 16 (2002), pp. 2079-2081
[55.]
M. Shah, K. Tierney, B. Adams-Huet, et al.
The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy.
HIV Med, 6 (2005), pp. 291-298
[56.]
H.O. Bang, J. Dyerberg, H.M. Sinclair.
The composition of the Eskimo food in north western Greenland.
Am J Clin Nutr, 33 (1980), pp. 2657-2661
[57.]
D.A. Wohl, H.C. Tien, M. Busby, et al.
Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Clin Infect Dis, 41 (2005), pp. 1498-1504
[58.]
J.G. Gerber, D.W. Kitch, C.J. Fichtenbaum, et al.
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
J Acquir Immune Defic Syndr, 47 (2008), pp. 459-466
[59.]
P. De Truchis, M. Kirstetter, A. Perier, et al.
Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.
J Acquir Immune Defic Syndr, 44 (2007), pp. 278-285
[60.]
L. Calza, R. Manfredi, F. Chiodo.
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
AIDS, 17 (2003), pp. 851-859
[61.]
E. Martínez, P. Leyes, E. Ros.
Effectiveness of lipid-lowering therapy in HIV patients.
Curr Opin HIV AIDS, 3 (2008), pp. 240-246
[62.]
K. Henry, H. Melroe, J. Huebesch, et al.
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Lancet, 352 (1998), pp. 1031-1032
[63.]
J. Miller, D. Brown, J. Amin, et al.
A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia.
AIDS, 16 (2002), pp. 2195-2200
[64.]
L. Calza, R. Manfredi, V. Colangeli, et al.
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
AIDS, 19 (2005), pp. 1051-1058
[65.]
L.A. Hajjar, D. Carleraro, P.C. Yu, et al.
Cardiovascular manifestations in patients infected with the human immunodeficiency virus.
Arq Bras Cardiol, 85 (2005), pp. 363-377
[66.]
M. Van der Lee, R. Sabkatsing, E. Schippers, et al.
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
Antivir Ther., 12 (2007), pp. 1127-1132
[67.]
R. Palacios, J. Santos, M. González, et al.
Efficacy and Safety of Atorvastatin in the Treatment of Hypercholesterolemia Associated With Antiretroviral Therapy.
J Acquir Immune Defic Syndr, 30 (2002), pp. 536-537
[68.]
B. Coll, G. Aragonés, S. Parra, et al.
Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.
AIDS, 20 (2006), pp. 1675-1677
[69.]
E. Negredo, J. Ribalta, R. Paredes, et al.
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
AIDS, 16 (2002), pp. 1383-1389
[70.]
M.T. Bennett, K.W. Johns, G.P. Bondy.
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Lipids Health Dis, 6 (2007), pp. 15
[71.]
L. Calza, R. Manfredi, F. Chiodo.
Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART.
Infection, 30 (2002), pp. 26-31
[72.]
J. Miller, D. Brown, J. Amin, et al.
A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitorassociated hypertriglyceridaemia.
AIDS, 16 (2002), pp. 2195-2200
[73.]
S. Badiou, C.M. De Boever, A. Dupuy, et al.
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Atherosclerosis, 172 (2004), pp. 273-279
[74.]
P.W.G. Mallon, J. Miller, J.C. Kovacic, J. Kent-Hughes, R. Norris, K. Samaras, M.P. Feneley, D.A. Cooper, A. Carr.
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected Men a randomized, placebo-controlled study.
AIDS, 20 (2006), pp. 1003-1010
[75.]
E. Negredo, J. Moltó, J. Puig, et al.
Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.
AIDS, 20 (2006), pp. 2159-2164
[76.]
C. Fisac, E. Fumero, M. Crespo, et al.
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
AIDS, 19 (2005), pp. 917-925
[77.]
P.H. Keiser, M.G. Sension, E. DeJesus, et al.
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
BMC Infect Dis, 5 (2005), pp. 2
[78.]
G.J. Moyle, C.A. Sabin, J. Cartledge, et al.
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
AIDS, 20 (2006), pp. 2043-2050
[79.]
J.M. Llibre, P. Domingo, R. Palacios, et al.
Sustained improvement of dyslipidaemia in HAART treated patients replacing stavudine with tenofovir.
AIDS, 20 (2006), pp. 1407-1414
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
